Australia's Somnomed hits 20-month high on Q1 revenue growth
26/10/2021 03:24
** Shares of sleep disorder treatment co Somnomed Ltd
SOM.AX rise as much as 8.2% to A$2.650, their highest since
March 3, 2020
** Co reports Q1 revenue of A$15.6 mln ($11.64 mln), up 14%
from a year earlier as business conditions across the northern
hemisphere improve and medical activity normalises urn:newsml:reuters.com:*:nGLF1QVLCs
** Co maintains FY22 revenue growth forecast of at least 15%
** Stock last up 6.1%, eyes best session since July 27
** SOM up 16.7% this year, as of last close
($1 = 1.3398 Australian dollars)
(Reporting by Jaskiran Singh in Bengaluru)
((Jaskiran.Singh@thomsonreuters.com))
Recent news on SomnoMed
See all newsAustralia's Somnomed jumps most in 7 months on strong half-year earnings
Brief: Somnomed® Increases Investment In Managed Care Infrastructure
Australia's Somnomed hits 32-month high on upbeat revenue growth
Brief: Somnomed Says Q1 FY26 Revenue Up 13.5% To A$28.7 Million
Brief: Somnomed Says FY EBITDA AUD 9.2 Million